Juvenile Arthritis

June 07, 2019

In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.

May 31, 2019

Early treatment with DMARDs for juvenile idiopathic arthritis polyarthritis is now preferred over beginning patients on NSAID monotherapy, per updated treatment guidelines. 

May 31, 2019

The American College of Rheumatology and the Arthritis Foundation have updated the 2013 treatment guidelines for juvenile idiopathic arthritis (JIA), which includes juvenile  non-systemic  polyarthritis,  sacroiliitis, and enthesitis. In this slideshow, we highlight the recommendations.

May 20, 2019

Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows.

May 09, 2019

Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.

March 04, 2019

Historically, treatments for children with systemic juvenile idiopathic arthritis (sJIA) have been difficult and ineffective, leading to poor outcomes. But, findings from a new study point to a method that could lead to more positive results.

December 21, 2018

Here’s a brief look at 6 medications for rheumatologic disorders that were newly approved in the second half of 2018.

November 21, 2018

The benefits and limitations of current technology and a look ahead to future advances.

October 24, 2018

New guidelines have been drafted for the treatment of JIA, specifically addressing therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis.

September 28, 2018

Ten evidence-based recommendations for the most commonly prescribed drug for JIA.